শেষ আপডেট: আগস্ট 15, 2026
A large part of my clinic is men who arrived with one number on a health-check report: a PSA above the 4.0 ng/mL cutoff. They are frequently very frightened by the time they sit down, and much of the consultation is spent explaining what that number does and does not mean. So let me start where I start with them.
An elevated PSA usually does not mean cancer. It means the prostate has leaked more of one particular enzyme into the blood than expected — and there are several ordinary reasons for that.
What PSA actually is
PSA stands for Prostate Specific Antigen, an enzyme made only by the prostate, whose job is to liquefy semen after ejaculation. It sits at high concentration inside prostate tissue and at very low concentration in the bloodstream. Anything that disturbs prostate tissue — an enlarged prostate, infection, or even minor manipulation of the gland — lets PSA leak into the blood and pushes the number up. When that happens without cancer being present, we call it a false positive.
Note what the name does নয় say: PSA is prostate-specific, not cancer-specific. That single distinction explains most of what follows.

Why screening everyone is no longer recommended
In 2018 a landmark US review concluded that universal PSA screening is not right for everyone: a modest benefit in men aged 55–69, and no benefit in men aged 70 and above. The reasoning is worth understanding rather than just accepting.
- The point of screening is to find high-risk localised prostate cancer, early enough to treat it successfully.
- Much prostate cancer is indolent — slow enough never to cause trouble. Autopsy studies found that about 33% of men who died of something else had prostate cancer nobody had detected, and it had not harmed them.
- Roughly 1 in 1,000 men screened genuinely benefits.
- False positives lead to biopsies that were not needed — with pain, blood in the urine or semen, and infection — and sometimes to treatment of a harmless cancer, which carries its own risks of erectile dysfunction and urinary incontinence.
Put plainly: screening can save a life, and it can also cause harm to a man who was never going to be harmed by his cancer. That is the trade-off, and it is why the recommendation is a conversation rather than a rule.

Who should start the conversation earlier
The 55–69 window applies to men at average risk. Some men are not at average risk and should raise it sooner, at around 40–45:
- A father or brother who has had prostate cancer
- Men of African descent, in whom prostate cancer occurs earlier and more aggressively
- A known family history of certain inherited cancer syndromes, which is worth mentioning to your doctor
One thing that has changed since 2018
Much of the harm in the list above comes from the assumption that a raised PSA leads more or less automatically to a needle biopsy. That is no longer the case. MRI of the prostate before biopsy can distinguish suspicious areas from an innocent gland, and spares a substantial proportion of men a biopsy they did not need. Where a biopsy is still required, the MRI-fusion transperineal technique targets the suspicious area rather than sampling blindly.
This matters for your decision: the balance of benefit and harm in a 2018 review reflected the pathway as it was then, and the harm side of that equation is smaller now than it was.
So what should you do?
If you are a man aged 55–69, discuss PSA screening with your doctor and reach a decision together, in the light of your own risk and your own view of the trade-off. It is genuinely your choice — there is no single right answer that applies to every man, which is exactly why the guidance stops short of telling you what to do.
And if you have already had a high result, do not panic before you have the full picture: here is what a high PSA actually means and what happens next. Screening is also only worth doing if effective treatment follows a positive result — you can read what that treatment involves on the prostate cancer surgery service page.
PSA স্ক্রিনিং সম্পর্কে আপনার প্রশ্ন থাকলে বা আপনার PSA পরীক্ষার ফলাফল বেশি হলে, ডাক্তার সোয়ারউই উইরাসুponে ব্যাংকক হাসপাতালের সদর দপ্তরে বিশেষজ্ঞ পরামর্শ প্রদান করেন।. পরামর্শ বুক করুন. Appointments at Samitivej Sriracha Hospital can be arranged by calling the Urology department on 088-022-1445.
PSA স্ক্রিনিং সম্পর্কিত প্রায়শই জিজ্ঞাসিত প্রশ্নাবলী
PSA (Prostate Specific Antigen) is a blood test that measures the level of an enzyme produced by the prostate gland. Elevated PSA may indicate prostate cancer, but it can also be raised by benign conditions such as BPH, prostatitis, or even minor prostatic manipulation. PSA is prostate-specific, not cancer-specific. It is used as a screening tool for prostate cancer, particularly in men aged 55–69, but must be interpreted carefully in context with other clinical information.
না। বর্তমান প্রমাণগুলি সার্বজনীন পিএসএ স্ক্রিনিং সমর্থন করে না। ২০১৮ সালের একটি যুগান্তকারী মার্কিন গবেষণায় দেখা গেছে যে ৫৫-৬৯ বছর বয়সী পুরুষদের জন্য সামান্য উপকারিতা রয়েছে, এবং ৭০ বছর বা তার বেশি বয়সী পুরুষদের জন্য কোনও উপকারিতা নেই। রুটিন স্ক্রিনিং মিথ্যা পজিটিভ ফলাফলের দিকে নিয়ে যেতে পারে, যার ফলে অপ্রয়োজনীয় উদ্বেগ এবং প্রোস্টেট বায়োপসি হতে পারে। স্ক্রিনিংয়ের সিদ্ধান্তটি রোগী এবং তাদের ডাক্তারের মধ্যে ভাগ করে নেওয়া সিদ্ধান্তের মাধ্যমে ব্যক্তিগতভাবে নেওয়া উচিত।.
পিএসএ (PSA) বৃদ্ধি মানেই প্রোস্টেট ক্যান্সার নয়। প্রোস্টেট-স্পেসিফিক অ্যান্টিজেন (PSA) বৃদ্ধির সাধারণ কারণগুলির মধ্যে প্রোস্টেটের সাধারণ বৃদ্ধি (BPH), প্রোস্টেটের প্রদাহ, মূত্রনালীর সংক্রমণ এবং প্রোস্টেটে সম্প্রতি কোনো পরীক্ষা বা হস্তক্ষেপ অন্তর্ভুক্ত। একজন ইউরোলজিস্ট বয়স, প্রোস্টেটের আকার, সময়ের সাথে সাথে PSA-এর পরিবর্তন এবং ক্লিনিকাল পরীক্ষার ফলাফলের নিরিখে PSA-এর মাত্রা বিচার করে প্রোস্টেট বায়োপসি (biopsy) করার পরামর্শ দেবেন। উচ্চ PSA সম্পন্ন অনেক পুরুষের ক্যান্সার থাকে না।.
The main risks of PSA screening stem from false positive results. A falsely elevated PSA may lead to a prostate biopsy, which carries risks including pain, hematuria (blood in urine), hematospermia (blood in semen), and infection. If biopsy leads to unnecessary treatment for indolent (non-harmful) cancer, additional risks include erectile dysfunction and urinary incontinence from surgery or radiation. Pre-biopsy MRI now spares many men a biopsy they would previously have undergone, which reduces this harm.
Current evidence supports considering PSA screening in men aged 55–69 after an informed discussion with a doctor about the potential benefits and harms. Men with higher risk – such as those with a first-degree relative with prostate cancer or men of African descent – may benefit from starting discussions earlier, around age 40–45. Men aged 70 and above generally do not benefit from PSA screening according to current guidelines.
দাবি পরিত্যাগ This content is written and reviewed by Dr. Soarawee Weerasopone, a board-certified urologist at Bangkok Hospital Headquarters. It is intended for educational purposes only and does not constitute medical advice. No medical advice, diagnosis or prescription is provided through personal messaging channels. Always consult a qualified healthcare professional before starting any medical treatment.
মেডিকেল লেখা এবং পর্যালোচিত: ডাঃ সোয়ারাউই উইরাসোপোন (ডাঃ পম) — বোর্ড-সার্টিফাইড ইউরোলজিস্ট, ব্যাংকক হাসপাতাল হেডকোয়ার্টার্স, ২০১৬ সাল থেকে ইউরোলজিক্যাল চিকিৎসায় নিয়োজিত। ফেলোশিপ: রোবোটিক সার্জারি, চ্যাং গুং মেমোরিয়াল হাসপাতাল, তাইওয়ান (২০১৯) · অবজার্ভারশিপ: এন্ডোইউরোলজি, জুনতেন্দো ইউনিভার্সিটি হাসপাতাল, টোকিও (২০২২) · রিসার্চ স্কলার ও ক্লিনিক্যাল অবজার্ভার, স্কট ডিপার্টমেন্ট অফ ইউরোলজি, বেলর কলেজ অফ মেডিসিন, ইউএসএ (২০২৫–২০২৬)।.

Dr. Soarawee Weerasopone (Dr. Pom) is a board-certified urologist at Bangkok Hospital Headquarters, specializing in Men’s Health, Robotic Surgery (da Vinci Xi) and Kidney Stone treatment. He is currently a Research Scholar and Clinical Observer at the Scott Department of Urology, Baylor College of Medicine (2025–2026), under Prof. Mohit Khera. He completed a Robotic Surgery Fellowship at Chang Gung Memorial Hospital, Taiwan (2019) and an Endourology Observership at Juntendo University Hospital, Tokyo (2022).


4 প্রতিক্রিয়া